Pharmacy Times
JULY 28, 2022
Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.
Pharmaceutical Technology
JULY 28, 2022
The Emergency Task Force (ETF) of the European Medicines Agency (EMA) has commenced the review of Veru’s sabizabulin to treat hospitalised Covid-19 patients at increased acute respiratory distress syndrome (ARDS) risk. The review will facilitate the use of the therapy for emergency usage in countries in the European Union (EU). Under this process, the ETF will analyse all available data, including findings from a trial in moderate-to-severe Covid-19 patients admitted to hospital who are at incre
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 28, 2022
The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.
pharmaphorum
JULY 28, 2022
Supply chain shortages have dominated headlines for several months, and the pharma industry has been no exception. While navigating changes has long been a challenge for the industry, the last two years’ events have made supply chain management significantly more difficult. The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceutical manufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JULY 28, 2022
People who performed 2 to 4 times above the recommended amount of moderate physical activity (300-600 minutes/week) saw an overall 26%-31% lower risk of mortality from all causes.
Pharmaceutical Technology
JULY 28, 2022
Ulcerative colitis (UC), an inflammatory bowel disease, is characterised by inflammation and ulcers in the large intestine, often causing symptoms that impact a patient’s quality of life, including diarrhoea, abdominal pain and cramping, fatigue, weight loss and pain. While the exact cause of UC remains unknown, it is often associated with immune system malfunction.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Technology
JULY 28, 2022
Bristol Myers Squibb (BMS) has reported a 2% rise in revenues to $11.9bn in the second quarter (Q2) of 2022 compared to $11.7bn in Q2 last year. The revenue growth was driven by in-line products, mainly Eliquis and Opdivo, as well as the company’s latest product portfolio comprising Abecma, Opdualag and Reblozyl. New LOE products, especially Revlimid and foreign exchange, impacts partially offset the increase in revenues.
Pharmacy Times
JULY 28, 2022
Currently, there is no treatment targeted for superoxide dismutase 1 amyotrophic lateral sclerosis, which has a life expectancy of 3 to 5 years from time of symptom onset.
Pharmaceutical Technology
JULY 28, 2022
Discontinuation or non-adherence to antipsychotic treatment is the most common cause of relapse in patients diagnosed with schizophrenia. As such, patients are typically offered continuous antipsychotic pharmacotherapy to prevent recurring episodes of psychosis. The use of long-acting injectable (LAI) formulations of these antipsychotics can help prevent hospitalisations related to symptom relapse, as these products are administered every fortnight or in one to six-month intervals, versus once o
Pharmacy Times
JULY 28, 2022
After a second booster dose, efficacy against COVID-19 Omicron subvariants rose to 80% within the first 6 months, according to results of a study by the CDC.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmaVoice
JULY 28, 2022
The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.
Pharmacy Times
JULY 28, 2022
Records from 11 million patients shows that non-alcoholic fatty liver disease could increase the risk of developing heart failure by 50%.
Outsourcing Pharma
JULY 28, 2022
A joint study conducted by analysts from Medable and the Center for the Study of Drug Development points toward shorter cycle times, cost savings, and more.
Pharmacy Times
JULY 28, 2022
The first thing is educating these folks, because it's hard for them to understand our challenges if they don’t understand what we do.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JULY 28, 2022
Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a “great start”, according to chief executive Giovanni Caforio. Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS’ PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by the FDA in March, and garnered $58 million in sales in the second quarter.
Pharmacy Times
JULY 28, 2022
They can assess for adherence, identify drug-related problems, monitor pharmacotherapy, and provide education.
PharmExec
JULY 28, 2022
Healthcare advertising agencies can now easily add retail pharmacies to their healthcare media buying strategies.
Pharmacy Times
JULY 28, 2022
Belimumab (Benlysta) the first FDA-approved therapy for pediatric lupus nephritis.
pharmaphorum
JULY 28, 2022
Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year earnings forecasts. Sales of Dupixent (dupilumab) rocketed 43% to €1.96 billion ($2 billion) – ahead of analyst expectations – driven by buoyant demand in its atopic dermatitis and severe asthma indications fuelled by approvals in earlier age groups.
Pharmacy Times
JULY 28, 2022
The drug combination demonstrated a 64.5% confirmed objective response rate in individuals with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.
Pharmaceutical Technology
JULY 28, 2022
Melinta Therapeutics has signed a licence agreement with Cidara Therapeutics to facilitate a strategic collaboration for marketing the latter’s rezafungin in the US. Rezafungin is a new, once-weekly echinocandin antifungal being developed by Cidara to treat and prevent serious fungal infections such as candidemia and invasive candidiasis in adults. It is also being developed for invasive fungal infection prophylaxis in adults who undergo allogeneic blood and marrow transplantation.
Pharmacy Times
JULY 28, 2022
Argatroban is indicated for thrombosis in adult patients with heparin-induced thrombocytopenia and as an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention.
Pharmaceutical Technology
JULY 28, 2022
Here are the largest chemical and pharmaceutical construction projects initiated globally in Q2 2022, according to GlobalData’s construction projects database. 1. Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore.
Pharmacy Times
JULY 28, 2022
Topical symptomatic relief for resistant skin conditions, including severe boils, hemorrhoids, eczema, cold sores, fungal infections, psoriasis, poison ivy, oak and sumac, and other itchy, painful conditions.
PharmExec
JULY 28, 2022
Montague will be responsible for developing and maintaining all relationships, activities and services for his client accounts while leading strategic and tactical planning initiatives for each of them.
Pharmacy Times
JULY 28, 2022
Get involved, attend their sessions, attend their conferences, understand what they’re saying, make sure that we’re, again, speaking with that one common voice.
Pharmaceutical Technology
JULY 28, 2022
The US Food and Drug Administration's (FDA) recent approval of Roche's Vabysmo (faricimab) for wet age-related macular degeneration (wAMD) in January this year, coupled with anticipated approval of pipeline therapies in the forecast period from 2021 to 2031, as well as potentially first-to-market therapies for geographic atrophy (GA), are all expected to drive the growth of the AMD market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan).
pharmaphorum
JULY 28, 2022
On the latest instalment of the pharmaphorum podcast, editor in chief Jonah Comstock hosts Dr Benny Alouf, chief medical officer at Limbix to discuss his company’s digital therapeutic for teen depression. Benny discusses SparkRx, Limbix’s product, and how it works, addressing the current regulatory landscape, how digital therapeutics interact with talk therapy and traditional therapeutics, and why it’s important to build a bespoke product for teens.
Pharmaceutical Technology
JULY 28, 2022
Osteoarthritis (OA) is a slowly progressive joint disease that is a major cause of disability and pain among the elderly, second only to cardiovascular disease. The OA space is characterised by a high level of unmet clinical need driven by the limited effectiveness of currently available analgesics and the lack of disease-modifying OA drugs (DMOADs).
Pharmacy Times
JULY 28, 2022
This month's featured products include iloperidone tablets, dabigatran etexilate capsules, and more.
Pharmaceutical Technology
JULY 28, 2022
Selecting a destination for a greenfield foreign direct investment (FDI) project is a long and sensitive process that no company takes lightly. By carefully weighing up a range of factors, businesses can ensure they are choosing a city or region where their company can access the resources needed to scale multinational operations smartly. In the life sciences sector, one country is significantly outstripping others for FDI.
Pharmaceutical Commerce
JULY 28, 2022
Faster approvals, more accurate and timely medicines monitoring—all enabled by harmonized, consistent and reliable data—will drive improved patient outcomes.
Pharmacy Times
JULY 28, 2022
The panel highlights opportunities for inclusive populations within trials for HR+/HER2- breast cancer, as well as pharmacist-led initiatives in clinical trial settings.
PharmExec
JULY 28, 2022
Braswell joins the organization to play an integral role in expanding POCN’s strategic and channel partnerships and leading the Business Development team.
Expert insights. Personalized for you.
139 
Let's personalize your content